Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Ibrutinib (Imbruvica) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 12 months; Continuation- 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Ibrutinib (Imbruvica).** Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: 1-866-331-2104]. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless this form is complete. The KP-MAS Formulary can be found at: http://pithelp.appl.kp.org/MAS/formulary.html**

1 – Patient Information

Patient Name: _____ Kaiser Medical ID#: _____ Date of Birth: _____

2 – Provider Information

Prescriber specialty: □ Hematologist □ Oncologist □ Other: _____

If consulted with a specialist, specialist name and specialty: _____

Provider Name: _____ Provider NPI: _____

Provider Address: _____

Provider Phone #: _____Provider Fax #: _____

Please check the boxes that apply:
□ Initial Request □ Continuation of Therapy Request

3 – Pharmacy Information

Pharmacy Name: _____ Pharmacy NPI: _____

Pharmacy Phone #_____ Pharmacy Fax #: _____

4 – Drug Therapy Requested

Drug 1: Name/Strength/Formulation: _____
Sig: _____

Drug 2: Name/Strength/Formulation: _____
Sig: _____

5 – Diagnosis

Indications:
□ Mantle Cell Lymphoma
□ Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL)
□ Waldenstrom's Macroglobinemia (WM)
□ Marginal Zone Lymphoma
□ Other: _____

6–Clinical Criteria

Initial Therapy:

Mantle Cell Lymphoma

1. Does the member have a diagnosis of mantle cell lymphoma and progression or relapse after one prior therapy?

   □ No □ Yes

Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL)

1. Does the member have a diagnosis of CLL/SLL with one of the following?
   a) □ No □ Yes Diagnosis of CLL/SLL with no known IGHV mutation
   b) □ No □ Yes Known IGHV mutation and history of failure, intolerance, or contraindication to fludarabine + cyclophosphamide + rituximab

Waldenstrom's Macroglobinemia (WM)

1. Member with symptomatic WM (e.g. hyperviscosity, neuropathy, symptomatic adenopathy or organomegaly, amyloidosis, cryoglobulinemia, cold agglutinin disease, and presence of cytopenia)

   □ No □ Yes

Marginal Zone Lymphoma

1. Does the member have relapsed or refractory marginal zone lymphoma after at least one anti- CD20-based therapy?

   □ No □ Yes

Continuation of Therapy:

1. Member does NOT show evidence of progressive disease while on therapy □ No □ Yes

7 – Provider Sign-Off

Additional Information – Please provide any additional information that should be taken into consideration.

_____

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Provider Signature:	**Date:**